drugset / Trial / NCT06922357
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.
Timeline
- Start
- 2025-04-24
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-6719 | Unknown | — | — |
Indications
No indication recorded.